National Research Corporation Total Assets 2011-2026 | NRC

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets National Research Corporation

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
122 M	130 M	158 M	133 M	111 M	108 M	127 M	121 M	129 M	130 M	111 M	100 M	101 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
158 M	100 M	122 M

Quarterly Total Assets National Research Corporation

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
136 M	141 M	135 M	133 M	132 M	119 M	-	122 M	120 M	134 M	134 M	130 M	135 M	-	153 M	158 M	156 M	152 M	147 M	133 M	133 M	133 M	133 M	111 M	111 M	111 M	111 M	108 M	108 M	108 M	108 M	127 M	127 M	127 M	127 M	121 M	121 M	121 M	121 M	128 M	128 M	128 M	128 M	130 M	130 M	130 M	130 M	111 M	111 M	111 M	111 M	100 M	100 M	100 M	100 M	101 M	101 M	101 M	101 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
158 M	100 M	123 M

Total Assets of other stocks in the Diagnostics research industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
Centogene N.V. CNTG	77.2 M	-	-6.23 %	$ 30.6 M	Germany
Akumin AKU	1.77 B	-	-17.87 %	$ 25.9 M	Canada
Aspira Women's Health AWH	17.4 M	-	-6.19 %	$ 10.5 M	USA
Burning Rock Biotech Limited BNR	2.28 B	$ 38.83	14.0 %	$ 442 M	China
Brainsway Ltd. BWAY	94.3 M	$ 23.3	-0.34 %	$ 99.4 M	Israel
Biocept BIOC	30.9 M	-	-13.05 %	$ 7.29 M	USA
Accelerate Diagnostics AXDX	65 M	-	-61.36 %	$ 2.46 M	USA
Castle Biosciences CSTL	531 M	$ 39.38	-0.03 %	$ 1.09 B	USA
BioNano Genomics BNGO	76.7 M	$ 1.26	-2.69 %	$ 1.6 M	USA
Check-Cap Ltd. CHEK	377 K	-	-	$ 9.42 M	Israel
Oxford Immunotec Global PLC OXFD	235 M	-	-	$ 562 M	Britain
Chembio Diagnostics CEMI	62.6 M	-	0.22 %	$ 16.8 M	USA
Exact Sciences Corporation EXAS	5.93 B	$ 102.49	0.14 %	$ 19 B	USA
Co-Diagnostics CODX	95.3 M	-	-	$ 79.8 M	USA
Danaher Corporation DHR	77.5 B	$ 222.92	1.85 %	$ 163 B	USA
DermTech DMTK	122 M	-	-11.32 %	$ 2.94 M	USA
Global Cord Blood Corporation CO	8.53 B	-	-	$ 399 M	China
Fluidigm Corporation FLDM	325 M	-	1.08 %	$ 308 M	USA
Genetic Technologies Limited GENE	20.8 M	-	-	$ 7.1 B	Australia
Guardant Health GH	1.49 B	$ 114.77	0.64 %	$ 14.1 B	USA
Genetron Holdings Limited GTH	975 M	-	0.12 %	$ 80.1 M	China
PRA Health Sciences, Inc. PRAH	4.18 B	-	-	$ 10.7 B	USA
DexCom DXCM	6.26 B	$ 72.79	-0.34 %	$ 28.1 B	USA
CareDx, Inc CDNA	467 M	$ 20.29	-1.27 %	$ 1.09 B	USA
Celcuity CELC	245 M	$ 111.76	2.14 %	$ 4.41 B	USA
DarioHealth Corp. DRIO	96.4 M	$ 10.74	7.19 %	$ 305 M	Israel
Enzo Biochem ENZ	85.8 M	-	-8.98 %	$ 14.8 K	USA
Fulgent Genetics FLGT	1.22 B	$ 26.0	-0.76 %	$ 786 M	USA
Lantheus Holdings LNTH	1.98 B	$ 66.88	-0.07 %	$ 4.63 B	USA
Medpace Holdings MEDP	2.1 B	$ 585.24	0.47 %	$ 18.1 B	USA
HTG Molecular Diagnostics HTGM	17.8 M	-	-20.0 %	$ 1.06 M	USA
Heska Corporation HSKA	586 M	-	-	$ 1.31 B	USA
IDEXX Laboratories IDXX	3.29 B	$ 636.25	-5.1 %	$ 52.5 B	USA
NeoGenomics NEO	1.64 B	$ 12.25	1.53 %	$ 1.55 B	USA
Illumina ILMN	6.3 B	$ 140.65	-2.87 %	$ 22.4 B	USA
QIAGEN N.V. QGEN	5.69 B	-	-	$ 10.6 B	Niderland
IQVIA Holdings IQV	26.9 B	$ 230.93	0.34 %	$ 41.9 B	USA
Charles River Laboratories International CRL	7.53 B	$ 212.06	0.7 %	$ 10.9 B	USA
Koninklijke Philips N.V. PHG	29 B	$ 28.84	0.47 %	$ 20 B	Niderland
Precipio PRPO	18.1 M	$ 24.75	0.9 %	$ 32.1 M	USA
Personalis PSNL	270 M	$ 9.28	-0.96 %	$ 550 M	USA
Quest Diagnostics Incorporated DGX	16.2 B	$ 184.48	-1.33 %	$ 20.5 B	USA
Biodesix BDSX	97.2 M	$ 10.24	0.69 %	$ 1.33 B	USA
Laboratory Corporation of America Holdings LH	18.4 B	$ 269.19	-0.86 %	$ 22.6 B	USA
ICON Public Limited Company ICLR	16.9 B	$ 176.3	-2.19 %	$ 14.5 B	Irlanda
Agilent Technologies A	10.7 B	$ 134.7	0.62 %	$ 40.9 B	USA
Biomerica BMRA	5.94 M	$ 2.39	0.63 %	$ 5.49 M	USA
OpGen OPGN	9.86 M	-	-16.95 %	$ 1.54 M	USA
Bioventus BVS	811 M	$ 8.23	3.78 %	$ 516 M	USA